Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
|Videos|June 29, 2016
Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases
Author(s)Veronica L. S. Chiang, MD
In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.
Advertisement
A new retrospective study found that patients with melanoma brain metastases who were treated with immunotherapy and stereotactic radiosurgery (SRS) within a month of each other had more robust and rapid tumor shrinkage.
In this video, senior study author Veronica L. S. Chiang, MD, of the Department of Neurosurgery at the Yale School of Medicine in New Haven, Connecticut, discusses the results of the study. Click here to
Advertisement
Related to this article
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.
The FDA has approved a FET-PET imaging agent, to help characterize recurrent or progressive glioma from treatment-related changes.
Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.
Josef Vymazal, MD, discussed a randomized study showing delayed double-dose gadopiclenol significantly improved detection of small brain metastases compared with standard imaging.
Josef Vymazal, MD, explained why high-relaxivity contrast agents are critical for detecting small brain metastases, despite weaker agents remaining suitable for other indications.
The first patient has been dosed in a phase 2 trial evaluating paxalisib plus gemcitabine in children and young adults with recurrent atypical teratoid/rhabdoid tumor.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Distinguishing HER2 Mutations From Amplification in NSCLC Testing
5